Umeclidinium bromide

Umeclidinium bromide

Clinical data
Trade names	Incruse Ellipta
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Inhalation (DPI)
ATC code	R03BB07 (WHO) R03AL03 (WHO) (+vilanterol)
Legal status
Legal status	US: ℞-only ℞ (Prescription only)
Pharmacokinetic data
Protein binding	~89%[1]
Metabolism	Hepatic (CYP2D6)
Biological half-life	11 hours
Excretion	Feces (58%) and urine (22%)
Identifiers
IUPAC name Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
Synonyms	GSK573719A
CAS Number	869113-09-7
PubChem (CID)	11519069
ChemSpider	9693857
ChEBI	CHEBI:79040
ECHA InfoCard	100.166.375
Chemical and physical data
Formula	C29H34BrNO2
Molar mass	508.49 g/mol
3D model (Jmol)	Interactive image
SMILES C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

Umeclidinium bromide (trade name Incruse Ellipta, GSK) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).^[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).^[2][3]

External links

• Incruse Ellipta (umeclidinium inhalation powder) Official Site

References

1. "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
2. Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
3. "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.